



Continuation of Substance of Interview including description of the general nature of what was discussed: In a follow-up to the interview of 30 July 2003, the parties discussed amending the claims such that they are directed to a tumor cell comprising the vaccinia virus vector of the invention. The examiner expressed concern that such claims might read on non-statutory subject matter (i.e., a human) and might lack utility..